Home  »  News   »  APLS’s Stochastic Averages Dip: Analyzing Ap...

APLS’s Stochastic Averages Dip: Analyzing Apellis Pharmaceuticals Inc.’s Stock Performance

Currently, the stock price of Apellis Pharmaceuticals Inc. (APLS) is $47.00. In the most recent trading session, the stock underwent a significant upswing, peaking at $47.1719 after opening at $43.88. The stock touched a low of $43.08 before closing at $44.44.

The market performance of Apellis Pharmaceuticals Inc. has been somewhat unstable. Over the past year, the company’s stock achieved a high of $94.75 on 06/14/23, with the lowest value for the same timeframe being $19.83, recorded on 08/07/23.

Top 5 EV Tech Stocks to Buy for 2023

The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".

Click Here to Download the FREE Report.


52-week price history of APLS Stock

Analyzing the 52-week price history of a stock, including its high and low prices, can provide valuable insight into its current status and potential future performance. Apellis Pharmaceuticals Inc.’s current trading price is -50.40% away from its 52-week high, while its distance from the 52-week low is 137.01%. The stock’s price range for this period has remained between $19.83 and $94.75. The Healthcare sector company’s shares managed to surpass a trading volume of around 2.63 million for the day, which was noticeably lower compared to the shares’ average daily volume of 4.83 million over the last three months.

Financial Performance and Market Capitalization

Apellis Pharmaceuticals Inc. (APLS) has experienced a quarterly decline of -47.35% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 5.39B and boasts a workforce of 767 employees.

Analysts’ Ratings For Apellis Pharmaceuticals Inc.

As of right now, 9 analysts are rating Apellis Pharmaceuticals Inc. as a BUY, 1 of the polled analysts branded the stock as an OVERWEIGHT, 5 analysts are recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 analyst is rating the stock as SELL.

Moving average and trading volume data

Based on Barchart.com data, the company’s moving average over the 100-day period was 64.26, with a change in price of -40.43. Similarly, Apellis Pharmaceuticals Inc. recorded 3,587,686 in trading volume during the last 100 days, posting a change of -46.24%.

APLS Debt-to-equity ratio analysis

The debt-to-equity (D/E) ratio is a valuable metric that offers insight into a company’s financial health and standing in the market. This ratio is calculated by dividing a company’s current total liabilities by its shareholders’ equity. The D/E ratio illustrates the extent of debt a company is utilizing to support its assets in relation to the value of its shareholders’ equity. At the time of writing, the total D/E ratio for APLS stands at 1.24. Similarly, the long-term debt-to-equity ratio is also 1.11.

APLS Stock Stochastic Average

As of today, the raw stochastic average of Apellis Pharmaceuticals Inc. over the past 50 days is 40.12%. This is a decrease compared to the raw stochastic average of the last 20 days, which was recorded at 98.98%. Additionally, the Stochastic %K and %D values for the company were 91.98% and 89.10%, respectively, over the past 20 days.

APLS Stock Price Performance Analysis

The performance of the stock price over the year has been up and down, leaving investors with either an optimistic or pessimistic outlook, depending on how they interpret the data. This year’s metric has recorded a Price decrease of -9.11%. However, over the past six months, we’ve seen a stronger performance of -25.42%. The price of APLS fallen by 52.10% over the last 30 days. And in the last five days, it has surged by 13.23%.

Leave a Comment

Your email address will not be published. Required fields are marked *

On Key

Related Posts